Published in J Virol on December 01, 1998
Replication-defective vector based on a chimpanzee adenovirus. J Virol (2001) 2.86
Structural and phylogenetic analysis of adenovirus hexons by use of high-resolution x-ray crystallographic, molecular modeling, and sequence-based methods. J Virol (2003) 2.10
Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther (2007) 1.94
Role of alpha(v) integrins in adenovirus cell entry and gene delivery. Microbiol Mol Biol Rev (1999) 1.90
Integrin alpha(v)beta1 is an adenovirus coreceptor. J Virol (2001) 1.72
Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus. J Clin Invest (1999) 1.56
Improved adenovirus vectors for infection of cardiovascular tissues. J Virol (2001) 1.55
Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res (2009) 1.51
Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov (2015) 1.47
Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. J Virol (2001) 1.43
Adenovirus vector pseudotyping in fiber-expressing cell lines: improved transduction of Epstein-Barr virus-transformed B cells. J Virol (2000) 1.37
Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon. J Virol (2002) 1.35
Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX. J Virol (2002) 1.35
Transductional targeting of adenovirus vectors for gene therapy. Cancer Gene Ther (2006) 1.34
Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J Virol (2000) 1.33
Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein. J Virol (2002) 1.33
Molecular engineering of viral gene delivery vehicles. Annu Rev Biomed Eng (2008) 1.28
Avidin-based targeting and purification of a protein IX-modified, metabolically biotinylated adenoviral vector. Mol Ther (2004) 1.26
A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. Clin Cancer Res (2010) 1.21
Identification of sites in adenovirus hexon for foreign peptide incorporation. J Virol (2005) 1.19
Protection against tetanus by needle-free inoculation of adenovirus-vectored nasal and epicutaneous vaccines. J Virol (2001) 1.19
Attenuation of Murray Valley encephalitis virus by site-directed mutagenesis of the hinge and putative receptor-binding regions of the envelope protein. J Virol (2001) 1.19
Current developments in adenovirus-based cancer gene therapy. Future Oncol (2006) 1.18
Genetically targeted adenovirus vector directed to CD40-expressing cells. J Virol (2003) 1.18
Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses (2010) 1.17
Metabolic biotinylation of recombinant proteins in mammalian cells and in mice. Mol Ther (2000) 1.16
Construction of a pseudoreceptor that mediates transduction by adenoviruses expressing a ligand in fiber or penton base. J Virol (1999) 1.08
Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol Ther (2010) 1.08
Localization of the N-terminus of minor coat protein IIIa in the adenovirus capsid. J Mol Biol (2008) 1.06
Functional and selective targeting of adenovirus to high-affinity Fcgamma receptor I-positive cells by using a bispecific hybrid adapter. J Virol (2001) 1.05
Genetic retargeting of adenovirus: novel strategy employing "deknobbing" of the fiber. J Virol (2001) 1.05
The coxsackievirus and adenovirus receptor acts as a tumour suppressor in malignant glioma cells. Br J Cancer (2003) 1.04
A phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer. Clin Cancer Res (2012) 1.04
Fiber and penton base capsid modifications yield diminished adenovirus type 5 transduction and proinflammatory gene expression with retention of antigen-specific humoral immunity. J Virol (2006) 1.03
Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach. Virol J (2008) 1.03
Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgene-arming capacity in oncolytic adenoviruses. Mol Ther (2010) 1.02
Adenoviral vector-based strategies for cancer therapy. Curr Drug ther (2009) 1.02
A chimeric type 2 adenovirus vector with a type 17 fiber enhances gene transfer to human airway epithelia. J Virol (1999) 1.02
Adenovirus type 5 viral particles pseudotyped with mutagenized fiber proteins show diminished infectivity of coxsackie B-adenovirus receptor-bearing cells. J Virol (2001) 0.99
Imaging chemically modified adenovirus for targeting tumors expressing integrin alphavbeta3 in living mice with mutant herpes simplex virus type 1 thymidine kinase PET reporter gene. J Nucl Med (2006) 0.99
Adenovirus receptors and their implications in gene delivery. Virus Res (2009) 0.98
Conditionally replicating adenoviruses for cancer treatment. Curr Cancer Drug Targets (2007) 0.98
Therapeutic molecular targeting of 15-lipoxygenase-1 in colon cancer. Mol Ther (2008) 0.97
Novel molecular approaches to cystic fibrosis gene therapy. Biochem J (2005) 0.96
Use of adenovirus vectors expressing Epstein-Barr virus (EBV) immediate-early protein BZLF1 or BRLF1 to treat EBV-positive tumors. J Virol (2002) 0.95
Modification of adenovirus capsid with a designed protein ligand yields a gene vector targeted to a major molecular marker of cancer. J Virol (2007) 0.94
Gene transfer for cystic fibrosis. J Clin Invest (1999) 0.94
Protein crystals in Adenovirus type 5-infected cells: requirements for intranuclear crystallogenesis, structural and functional analysis. PLoS One (2008) 0.93
Targeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenoviruses. J Thorac Oncol (2006) 0.93
Targeting adenoviral vectors by using the extracellular domain of the coxsackie-adenovirus receptor: improved potency via trimerization. J Virol (2002) 0.92
Artificial extension of the adenovirus fiber shaft inhibits infectivity in coxsackievirus and adenovirus receptor-positive cell lines. J Virol (2002) 0.92
Targeting EGFR with metabolically biotinylated fiber-mosaic adenovirus. Gene Ther (2007) 0.91
Antibody-mediated targeting of an adenovirus vector modified to contain a synthetic immunoglobulin g-binding domain in the capsid. J Virol (2003) 0.91
Chapter two--Adenovirus strategies for tissue-specific targeting. Adv Cancer Res (2012) 0.90
Conditionally replicating adenovirus expressing TIMP2 for ovarian cancer therapy. Clin Cancer Res (2010) 0.90
Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes. Retrovirology (2011) 0.90
Redirecting lentiviral vectors by insertion of integrin-tageting peptides into envelope proteins. J Gene Med (2009) 0.89
Tropism modification of adenovirus vectors by peptide ligand insertion into various positions of the adenovirus serotype 41 short-fiber knob domain. J Virol (2006) 0.89
Radiotherapy sensitization by tumor-specific TRAIL gene targeting improves survival of mice bearing human non-small cell lung cancer. Clin Cancer Res (2005) 0.89
Intraductal delivery of adenoviruses targets pancreatic tumors in transgenic Ela-myc mice and orthotopic xenografts. Oncotarget (2013) 0.89
Adenoviral virotherapy for malignant brain tumors. Expert Opin Biol Ther (2009) 0.88
Increasing the efficacy of oncolytic adenovirus vectors. Viruses (2010) 0.88
In vivo retargeting of adenovirus type 5 to alphavbeta6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery. J Virol (2009) 0.88
HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications. Neoplasia (1999) 0.88
A rapid and efficient method for purification of recombinant adenovirus with arginine-glycine-aspartic acid-modified fibers. Anal Biochem (2006) 0.88
Usage of integrin and heparan sulfate as receptors for mouse adenovirus type 1. J Virol (2009) 0.88
Retargeting of adenovirus vectors through genetic fusion of a single-chain or single-domain antibody to capsid protein IX. J Virol (2010) 0.88
Targeting the urokinase plasminogen activator receptor enhances gene transfer to human airway epithelia. J Clin Invest (2000) 0.87
Redirecting coronavirus to a nonnative receptor through a virus-encoded targeting adapter. J Virol (2006) 0.87
Gene therapy of benign gynecological diseases. Adv Drug Deliv Rev (2009) 0.87
Prospects for oral replicating adenovirus-vectored vaccines. Vaccine (2013) 0.86
Oncolytic adenoviruses armed with thymidine kinase can be traced by PET imaging and show potent antitumoural effects by ganciclovir dosing. PLoS One (2011) 0.86
Codelivery of the chemokine CCL3 by an adenovirus-based vaccine improves protection from retrovirus infection. J Virol (2011) 0.86
RGD peptide-modified adenovirus expressing hepatocyte growth factor and X-linked inhibitor of apoptosis improves islet transplantation. J Gene Med (2011) 0.85
A pRb-responsive, RGD-modified, and hyaluronidase-armed canine oncolytic adenovirus for application in veterinary oncology. Mol Ther (2014) 0.85
A new generation of serotype chimeric infectivity-enhanced conditionally replicative adenovirals: the safety profile of ad5/3-Δ24 in advance of a phase I clinical trial in ovarian cancer patients. Hum Gene Ther (2011) 0.85
Enhancement of adenovirus vector entry into CD70-positive B-cell Lines by using a bispecific CD70-adenovirus fiber antibody. J Virol (2001) 0.85
Current progress in the development of a prophylactic vaccine for HIV-1. Drug Des Devel Ther (2010) 0.85
Mining the adenovirus virome for oncolytics against multiple solid tumor types. Cancer Gene Ther (2011) 0.84
Coxsackievirus and adenovirus receptor expression in human endometrial adenocarcinoma: possible clinical implications. World J Surg Oncol (2008) 0.84
Ephrin A2 receptor targeting does not increase adenoviral pancreatic cancer transduction in vivo. World J Gastroenterol (2009) 0.84
Development of a targeted gene vector platform based on simian adenovirus serotype 24. J Virol (2010) 0.84
Adenovirus i-leader truncation bioselected against cancer-associated fibroblasts to overcome tumor stromal barriers. Mol Ther (2011) 0.84
Advanced generation adenoviral virotherapy agents embody enhanced potency based upon CAR-independent tropism. Clin Cancer Res (2006) 0.84
Derivation of a myeloid cell-binding adenovirus for gene therapy of inflammation. PLoS One (2012) 0.84
A conditionally replicative adenovirus, CRAd-S-pK7, can target endometriosis with a cell-killing effect. Hum Reprod (2010) 0.84
Development of peritoneal tumor-targeting vector by in vivo screening with a random peptide-displaying adenovirus library. PLoS One (2012) 0.83
Targeting of mesenchymal stem cells to ovarian tumors via an artificial receptor. J Ovarian Res (2010) 0.83
Phage display of adenovirus type 5 fiber knob as a tool for specific ligand selection and validation. J Virol (2001) 0.83
Gene Therapies for Cancer: Strategies, Challenges and Successes. J Cell Physiol (2015) 0.83
Targeting adeno-associated virus and adenoviral gene therapy for hepatocellular carcinoma. World J Gastroenterol (2016) 0.83
Arming a replicating adenovirus with osteoprotegerin reduces the tumor burden in a murine model of osteolytic bone metastases of breast cancer. Cancer Gene Ther (2010) 0.82
Gene transfer of active Akt1 by an infectivity-enhanced adenovirus impacts β-cell survival and proliferation differentially in vitro and in vivo. Islets (2012) 0.82
Identification of HI-like loop in CELO adenovirus fiber for incorporation of receptor binding motifs. J Virol (2007) 0.82
Tumor-specific apoptotic gene targeting overcomes radiation resistance in esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys (2006) 0.82
Enhanced transduction and replication of RGD-fiber modified adenovirus in primary T cells. PLoS One (2011) 0.82
Adenoviral vector-mediated gene therapy for gliomas: coming of age. Expert Opin Biol Ther (2014) 0.82
A genetically retargeted adenoviral vector enhances viral transduction in esophageal carcinoma cell lines and primary cultured esophageal resection specimens. Ann Surg (2003) 0.82
Barriers to systemic application of virus-based vectors in gene therapy: lessons from adenovirus type 5. Virus Genes (2017) 0.82
Integrins: versatility, modulation, and signaling in cell adhesion. Cell (1992) 34.06
Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science (1997) 14.41
Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell (1993) 13.21
Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science (1998) 8.11
The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology (1968) 7.42
HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci U S A (1997) 6.92
Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol (1996) 5.71
Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol (1996) 4.97
Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol (1994) 4.65
Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol (1997) 3.89
The cell attachment site on foot-and-mouth disease virus includes the amino acid sequence RGD (arginine-glycine-aspartic acid). J Gen Virol (1989) 3.53
Integrin alpha v beta 5 selectively promotes adenovirus mediated cell membrane permeabilization. J Cell Biol (1994) 3.42
Mutations that alter an Arg-Gly-Asp (RGD) sequence in the adenovirus type 2 penton base protein abolish its cell-rounding activity and delay virus reproduction in flat cells. J Virol (1993) 3.29
Multiple adenovirus serotypes use alpha v integrins for infection. J Virol (1994) 2.86
Crystal structure of the receptor-binding domain of adenovirus type 5 fiber protein at 1.7 A resolution. Structure (1994) 2.80
Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat Biotechnol (1996) 2.69
Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol (1997) 2.64
Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol (1996) 2.52
The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. J Virol (1998) 2.45
Integrins and cancer. Curr Opin Cell Biol (1996) 2.44
Selection of peptides binding to the alpha 5 beta 1 integrin from phage display library. J Biol Chem (1993) 2.37
Cell-binding domain of adenovirus serotype 2 fiber. J Virol (1994) 2.16
Infectious entry pathway of adenovirus type 2. J Virol (1991) 2.06
Entry of coxsackievirus A9 into host cells: specific interactions with alpha v beta 3 integrin, the vitronectin receptor. Virology (1994) 1.96
The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. Proc Natl Acad Sci U S A (1993) 1.93
RGD-dependent entry of coxsackievirus A9 into host cells and its bypass after cleavage of VP1 protein by intestinal proteases. J Virol (1991) 1.91
Site-directed and linker insertion mutagenesis of herpes simplex virus type 1 glycoprotein H. J Virol (1997) 1.88
Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J Virol (1998) 1.88
Cryo-EM visualization of an exposed RGD epitope on adenovirus that escapes antibody neutralization. EMBO J (1997) 1.82
Isolation of a highly specific ligand for the alpha 5 beta 1 integrin from a phage display library. J Cell Biol (1994) 1.80
Adhesion molecules in cancer: the role of integrins. Curr Opin Cell Biol (1993) 1.72
Vitronectin receptor antibodies inhibit infection of HeLa and A549 cells by adenovirus type 12 but not by adenovirus type 2. J Virol (1994) 1.63
A decay-accelerating factor-binding strain of coxsackievirus B3 requires the coxsackievirus-adenovirus receptor protein to mediate lytic infection of rhabdomyosarcoma cells. J Virol (1997) 1.63
Human neural cell adhesion molecule L1 and rat homologue NILE are ligands for integrin alpha v beta 3. J Cell Biol (1996) 1.50
Addition of a short peptide ligand to the adenovirus fiber protein. Gene Ther (1995) 1.42
Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas. Int J Cancer (1997) 1.40
Domains required for assembly of adenovirus type 2 fiber trimers. J Virol (1996) 1.35
Oligomerization of recombinant penton base of adenovirus type 2 and its assembly with fiber in baculovirus-infected cells. Virology (1994) 1.25
Crystal structure of the top domain of African horse sickness virus VP7: comparisons with bluetongue virus VP7. J Virol (1996) 1.06
Efficient RGD-independent entry process of coxsackievirus A9. Arch Virol (1996) 0.90
A phase I study of recombinant adenovirus vector-mediated intraperitoneal delivery of herpes simplex virus thymidine kinase (HSV-TK) gene and intravenous ganciclovir for previously treated ovarian and extraovarian cancer patients. Hum Gene Ther (1997) 0.90
Specific interactions between human integrin alpha v beta 3 and chimeric hepatitis B virus core particles bearing the receptor-binding epitope of foot-and-mouth disease virus. Virology (1997) 0.85
A phase I study of recombinant adenovirus vector-mediated delivery of an anti-erbB-2 single-chain (sFv) antibody gene for previously treated ovarian and extraovarian cancer patients. Hum Gene Ther (1997) 0.84
Chimeric hepatitis B virus core particles as probes for studying peptide-integrin interactions. J Virol (1996) 0.84
The sequence of the human genome. Science (2001) 101.55
Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J Virol (1992) 8.35
Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol (2001) 8.25
Sequence and genomic organization of Norwalk virus. Virology (1993) 6.25
The 5th National Audit Project (NAP5) on accidental awareness during general anaesthesia: summary of main findings and risk factors. Anaesthesia (2014) 4.07
Appropriateness of the decision to transfer nursing facility residents to the hospital. J Am Geriatr Soc (2000) 3.99
Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med (2001) 3.81
The small ubiquitin-like modifier-1 (SUMO-1) consensus sequence mediates Ubc9 binding and is essential for SUMO-1 modification. J Biol Chem (2001) 3.64
Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J Immunol (1998) 3.03
Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene (1990) 2.97
Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol (2007) 2.97
Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol (1999) 2.94
PDR5, a novel yeast multidrug resistance conferring transporter controlled by the transcription regulator PDR1. J Biol Chem (1994) 2.92
Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity (1999) 2.67
The topography of awareness: a classification of intra-operative cognitive states. Anaesthesia (2012) 2.61
Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol (1996) 2.52
Direct sequencing of the HA gene of influenza (H3N2) virus in original clinical samples reveals sequence identity with mammalian cell-grown virus. J Virol (1990) 2.45
Are nonspecific practice guidelines potentially harmful? A randomized comparison of the effect of nonspecific versus specific guidelines on physician decision making. Health Serv Res (2000) 2.45
Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface of human epithelial and B lymphoblastoid cells. EMBO J (1997) 2.43
Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J Virol (2001) 2.42
Interplay of electron-lattice interactions and superconductivity in superconductivity in Bi2Sr2CaCu2O8+delta. Nature (2006) 2.40
Blood clearance rates of adenovirus type 5 in mice. J Gen Virol (2000) 2.36
Establishment, maintenance and description of cell lines from the tick Ixodes scapularis. J Parasitol (1994) 2.36
In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver. Bioconjug Chem (2000) 2.30
Crystal structures of medium-chain acyl-CoA dehydrogenase from pig liver mitochondria with and without substrate. Proc Natl Acad Sci U S A (1993) 2.29
Retrieval of water-leaving radiance and aerosol optical thickness over the oceans with SeaWiFS: a preliminary algorithm. Appl Opt (1994) 2.28
Absence of specific mucosal antibody responses in HIV-exposed uninfected sex workers from the Gambia. AIDS (2000) 2.26
Error-free and error-prone lesion bypass by human DNA polymerase kappa in vitro. Nucleic Acids Res (2000) 2.25
Rapid, nonradioactive detection of mutations in the human genome by allele-specific amplification. J Lab Clin Med (1989) 2.22
Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts. Cell Immunol (2000) 2.18
Fractal model of ion-channel kinetics. Biochim Biophys Acta (1987) 2.17
Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotechnol (1996) 2.14
Specificity of DNA lesion bypass by the yeast DNA polymerase eta. J Biol Chem (2000) 2.12
Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci U S A (1998) 2.11
Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc Natl Acad Sci U S A (1997) 2.11
FIN219, an auxin-regulated gene, defines a link between phytochrome A and the downstream regulator COP1 in light control of Arabidopsis development. Genes Dev (2000) 2.11
DNA-binding properties of Arabidopsis MADS domain homeotic proteins APETALA1, APETALA3, PISTILLATA and AGAMOUS. Nucleic Acids Res (1996) 2.06
Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing. Cancer Res (1997) 2.05
Localization of iodine-125-mIP-Des-Met14-bombesin (7-13)NH2 in ovarian carcinoma induced to express the gastrin releasing peptide receptor by adenoviral vector-mediated gene transfer. J Nucl Med (1997) 2.05
IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol (1995) 2.02
Human nonmuscle myosin heavy chains are encoded by two genes located on different chromosomes. Circ Res (1991) 1.98
CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther (2001) 1.92
Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem (1996) 1.92
High-efficiency receptor-mediated delivery of small and large (48 kilobase gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles. Proc Natl Acad Sci U S A (1992) 1.90
Characterization of a new avian-like influenza A virus from horses in China. Virology (1992) 1.90
Replicative adenoviruses for cancer therapy. Nat Biotechnol (2000) 1.89
Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J Virol (1998) 1.88
Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1. J Virol (1998) 1.87
The 5th National Audit Project (NAP5) on accidental awareness during general anaesthesia: patient experiences, human factors, sedation, consent and medicolegal issues. Anaesthesia (2014) 1.85
Fourteen-year follow-up of children with and without speech/language impairments: speech/language stability and outcomes. J Speech Lang Hear Res (1999) 1.84
Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia (2013) 1.84
Protein kinase C overactivity impairs prefrontal cortical regulation of working memory. Science (2004) 1.83
Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat Biotechnol (2001) 1.83
Dominant negative guard cell K+ channel mutants reduce inward-rectifying K+ currents and light-induced stomatal opening in arabidopsis. Plant Physiol (2001) 1.82
Isolation of influenza C virus from pigs and experimental infection of pigs with influenza C virus. J Gen Virol (1983) 1.81
Current burden and probable increasing incidence of ESRD in China. Clin Nephrol (2010) 1.74
Biomarkers of environmental tobacco smoke in preschool children and their mothers. J Natl Cancer Inst (1994) 1.72
Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes. Proc Natl Acad Sci U S A (1992) 1.72
Synaptic connections from large muscle afferents to the motoneurons of various leg muscles in man. Exp Brain Res (1984) 1.71
HuA and tristetraprolin are induced following T cell activation and display distinct but overlapping RNA binding specificities. J Biol Chem (2001) 1.71
Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammary epithelial cells. Proc Natl Acad Sci U S A (1996) 1.70
Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene (2006) 1.70
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector. Nat Biotechnol (1997) 1.66
The tricornered gene, which is required for the integrity of epidermal cell extensions, encodes the Drosophila nuclear DBF2-related kinase. Genetics (2000) 1.65
Bacterial expression and characterization of a cDNA for human liver estrogen sulfotransferase. J Steroid Biochem Mol Biol (1995) 1.65
2,2-Diphenyl-1-picrylhydrazyl radical-scavenging active components from Polygonum multiflorum thunb. J Agric Food Chem (1999) 1.64
Rational modification of protein stability by the mutation of charged surface residues. Biochemistry (2000) 1.62
Adamantinoma-like Ewing's sarcoma: genomic confirmation, phenotypic drift. Am J Surg Pathol (1999) 1.61
Characterization of infectivity of knob-modified adenoviral vectors in glioma. Cancer Biol Ther (2008) 1.61
Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res (1998) 1.59
Induction of specific T-cell tolerance by adenovirus-transfected, Fas ligand-producing antigen presenting cells. Nat Biotechnol (1998) 1.59
Left ventricular long axis function in diastolic heart failure is reduced in both diastole and systole: time for a redefinition? Heart (2002) 1.58
Ethnic differences in the prevalence of the homozygous deleted genotype of glutathione S-transferase theta. Carcinogenesis (1995) 1.57
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Serum proteomic profiling in patients with drug-induced liver injury. Aliment Pharmacol Ther (2012) 1.55
Corticotropin releasing factor produces increases in brain excitability and convulsive seizures in rats. Brain Res (1983) 1.55
Nasal challenge with diesel exhaust particles can induce sensitization to a neoallergen in the human mucosa. J Allergy Clin Immunol (1999) 1.54
Absence of memory for intraoperative information during surgery under adequate general anaesthesia. Br J Anaesth (1997) 1.51
Aromatic DNA adducts in adjacent tissues of breast cancer patients: clues to breast cancer etiology. Cancer Res (1996) 1.51
The alpha 1-antitrypsin gene and its mutations. Clinical consequences and strategies for therapy. Chest (1989) 1.51
Quantitative DNA fiber mapping. Hum Mol Genet (1995) 1.50
Troponin T, left ventricular mass, and function are excellent predictors of cardiovascular congestion in peritoneal dialysis. Kidney Int (2006) 1.50
Histogenesis of sarcomatoid urothelial carcinoma of the urinary bladder: evidence for a common clonal origin with divergent differentiation. J Pathol (2007) 1.50
Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med (1996) 1.49
Prevalence of myasthenia gravis and associated autoantibodies in paraneoplastic pemphigus and their correlations with symptoms and prognosis. Br J Dermatol (2015) 1.49
Improved GFR estimation by combined creatinine and cystatin C measurements. Kidney Int (2007) 1.48
Acute effects of thirty minutes of light-intensity, intermittent exercise on patients with chronic fatigue syndrome. Phys Ther (1999) 1.48
Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody. Gynecol Oncol (1995) 1.47
The clinical value of rapid assay for plasma B-type natriuretic peptide in differentiating congestive heart failure from pulmonary causes of dyspnoea. Int J Clin Pract (2007) 1.46
A clinical rating scale for Batten disease: reliable and relevant for clinical trials. Neurology (2005) 1.45
Notch3 signaling initiates choroid plexus tumor formation. Oncogene (2006) 1.43
A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res (2001) 1.43
Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. J Virol (2001) 1.43